Source: Annual Congress 2009 - Drug effects in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Saito, K. Shimizu, M. Matsuyama, N. Kokuho, Y. Miura, S. Otsuka, T. Kiwamoto, K. Hayashihara (Tokai-mura, Japan). Survey of dyspnoea in COPD patients on medication and preemptive use of a short-acting β-2 agonist. Eur Respir J 2009; 34: Suppl. 53, 2002

Member's Comments

No comment yet.

Related content which might interest you: Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012 Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Once-daily QVA149 improves symptom scores in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Impact of add-on medications on patient‘s satisfaction in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 273s Year: 2005